相关实验视频

Updated: Feb 20, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

YMN-V115:一种新型的人性化BCMA/GPRC5D/CD3三种特异性抗体,用于复发性/耐药性多发性骨髓瘤

Jia Li¹, Qizhong Lu¹, Zhixiong Zhu¹

¹State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China.

Journal for immunotherapy of cancer

|February 18, 2026

概括

一种新的三特异性抗体YMN-V115通过向BCMA和GPRC5D.通过向BCMA和GPRC5D.通过向BCMA和GPRC5D.通过向BCMA和GPRC5D.通过向BCMA和GPRC5D.通过向BCMA. 这种新疗法克服了抗原逃逸和免疫逃避,为复发或耐药的MM患者提供了希望.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
生物技术是生物技术.

背景情况:

多发性骨髓瘤 (MM) 是一种复发性血液癌症,其需求尚未得到满足.
BCMA和GPRC5D是经过验证的MM标,但双特异性抗体面临限制.
抗原逃逸和免疫逃避阻碍了目前的治疗有效性.

研究的目的:

开发一种新的三种特异性抗体,用于增强MM治疗.
克服现有的双特异性治疗方法的局限性.
同时准BCMA,GPRC5D和CD3以改善T细胞参与.

主要方法:

一种人性化的三特异性抗体,YMN-V115,是以1+1+1格式设计的.
YMN-V115包含了BCMA,GPRC5D和CD3.3的结合部位.
使用临床前的体外和体内模型来评估疗效和毒性.

主要成果:

与双特异性抗体相比,YMN-V115对MM细胞表现出更高的细胞毒性.
即使存在可溶性BCMA,也保持了有效性,表明对诱抑制的抵抗力.
该抗体有效地向BCMA+和GPRC5D+瘤细胞,增强T细胞激活和瘤控制.

结论:

YMN-V115是一种下一代三特异性T细胞参与者,用于MM.
它有效地解决了抗原异质性和免疫逃避问题.
临床前数据支持YMN-V115在复发性/耐药性MM的临床发展.

关键词:

抗体是对抗体的一种.双特异性T细胞参与者 - BiTE 免疫治疗是一种免疫疗法.多发性骨髓瘤是多发性骨髓瘤的一种.

更多相关视频

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...